First Case Report Associating Gemcitabine with Hypersensitivity Reaction in a Patient with Pancreatic Cancer
Abstract
No abstract available.
Image: Ball-and-stick model of the protonated gemcitabine cation and the nearest chloride anion (Author: Benn Mils; Wikimedia Commons).
Downloads
References
Lilly Oncology. Gemzar: gemcitabine HCl. Eli Lilly and Company, Indianapolis, IN, USA. (Last assessed Dec 04, 2009).
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978]
Saif MW. Is There a Standard of Care for the Management of Advanced Pancreatic Cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2007. JOP. J Pancreas (Online) 2008; 9:91-8. [PMID 18326919]
Li J, Ko CJ, Saif MW. Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer. Cutan Ocul Toxicol 2009; 28:144-8. [PMID 19527102]
Imen A, Amal K, Ines Z, Sameh el F, Fethi el M, Habib G. Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma. Respir Med 2006; 100:1463-5. [PMID 16434173]
Chu CY, Yang CH, Chiu HC. Gemcitabine-induced acute lipodermatosclerosis-like reaction. Acta Derm Venereol 2001; 81:426-8. [PMID 11859947]
I Kuku, E Kaya, A Sevinc, I Aydogdu. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol 2002; 16:271-2. [PMID 12195570]
Copyright (c) 2010 Muhammad Wasif Saif, Paula Chakerian, Kristin Kaley, Lynne Lamb
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.